Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

Autor: Antonio Bertolotto, Rafael Arroyo, Elisabeth G. Celius, Giancarlo Comi, Eva Kubala Havrdova, William David Honeycutt, Samuel F. Hunter, Guillermo Izquierdo, Barbara Kornek, Tamara Miller, Dimos D. Mitsikostas, Barry A. Singer, Tjalf Ziemssen, Luke Chung, Nadia Daizadeh, Salman Afsar, Lobat Hashemi, Peter Senior

Publikováno v: Neurology and Therapy, Vol 9, Iss 2, Pp 443-457 (2020)

Plain Language Summary This study looked at alemtuzumab, an approved treatment for multiple sclerosis (MS). People who receive alemtuzumab may develop thyroid problems. The researchers wanted to know whether people who developed thyroid problems with

Externí odkaz: https://doaj.org/article/3bcc37fc46e84de69be4eb2c49df7148

Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

Autor: Luke Chung, Samuel F. Hunter, Barry A Singer, Antonio Bertolotto, Guillermo Izquierdo, Lobat Hashemi, Tjalf Ziemssen, Nadia Daizadeh, William David Honeycutt, Elisabeth Gulowsen Celius, Dimos-Dimitrios Mitsikostas, Salman Afsar, Barbara Kornek, Tamara Miller, Peter A. Senior, Rafael Arroyo, Giancarlo Comi, Eva Havrdova

Publikováno v: Neurology and Therapy, Vol 9, Iss 2, Pp 443-457 (2020)
Neurology and Therapy

Introduction In clinical trials of alemtuzumab, autoimmune thyroid adverse events (AEs) were frequent. Here, we assess the impact of thyroid AEs on health-related quality of life (HRQL) in alemtuzumab-treated patients with relapsing-remitting multipl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11cd63ac06d46041c4b97e966e3dc953
https://doaj.org/article/3bcc37fc46e84de69be4eb2c49df7148

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma.

Autor: Song YS; Division of Endocrinology and Metabolism, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea.; Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, South Korea., Yang H; Division of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea., Kang B; Division of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea., Cheon J; Division of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea., Kim I; Division of Oncology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea., Kim H; Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea., Lee WS; Division of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea., Sang YB; Division of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea., Jung S; Department of Radiology, CHA Bundang Medical Center, Seongnam, South Korea., Lim HY; Division of Hemato-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Gaillard VE; F. Hoffmann-La Roche Ltd., Basel, Switzerland., Kim C; Division of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea., Chon HJ; Division of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea.

Publikováno v: Liver cancer [Liver Cancer] 2023 May 25; Vol. 13 (1), pp. 89-98. Date of Electronic Publication: 2023 May 25 (Print Publication: 2024).